When Roche's Genentech gained approval for Ocrevus in 2017, the first-in-class infused drug quickly became the best-selling treatment in a crowded multiple sclerosis (MS) market. Three years later ...
Swiss pharma giant Roche won approval from the Food and Drug Administration on Friday for an injectable version of its blockbuster multiple sclerosis therapy Ocrevus, cutting down the time needed ...
Sept 12 (Reuters) - Stories on Roche receiving FDA approval for an injectable version of its multiple sclerosis therapy are incorrect and are withdrawn. There will be no replacement story.
The father of one was 31 when he was last seen alive in Kilkenny Dean Roche's car was found crashed into a tree Gardaí are to launch a review of the mysterious case of a man who was aged 31 when ...
FRANKFURT, Sept 11 (Reuters) - Roche (ROG.S), opens new tab said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July ...
Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage trials, the pharma’s head of metabolism R&D has told Fierce Biotech.
Roche’s new weight loss candidate has the efficacy the Swiss pharma was looking for. But it also comes with a high rate of side effects … ...
Roche Holding AG said it isn’t concerned about side effects in a small study of a weight-loss shot, after details about the trial sent shares tumbling on Monday. “We’re not alarmed at all ...
(Bloomberg) -- Shares of Roche Holding AG fell after a poster highlighted side effects in an early-stage study of the Swiss pharmaceutical company’s experimental obesity medicine. The poster, released ...
Shares of Roche Holding AG fell after a poster highlighted side effects in an early-stage study of the Swiss pharmaceutical company’s experimental obesity medicine. The poster, released as part ...
Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the primary endpoint in a Phase III trial for progressive MS but flopped in two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback